Cargando…

Inhibition of myostatin improves muscle atrophy in oculopharyngeal muscular dystrophy (OPMD)

BACKGROUND: Oculopharyngeal muscular dystrophy (OPMD) is a late‐onset muscle disease affecting one per 80 000 of the general population characterized by profound dysphagia and ptosis, and limb weakness at later stages. Affected muscles are characterized by increased fibrosis and atrophy. Myostatin i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harish, Pradeep, Malerba, Alberto, Lu‐Nguyen, Ngoc, Forrest, Leysa, Cappellari, Ornella, Roth, Fanny, Trollet, Capucine, Popplewell, Linda, Dickson, George
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818462/ https://www.ncbi.nlm.nih.gov/pubmed/31066242 http://dx.doi.org/10.1002/jcsm.12438

Ejemplares similares

Inhibition of Myostatin Reduces Collagen Deposition in a Mouse Model of Oculopharyngeal Muscular Dystrophy (OPMD) With Established Disease
por: Harish, Pradeep, et al.
Publicado: (2020)

Novel Metabolomic Approach for Identifying Pathology-Specific Biomarkers in Rare Diseases: A Case Study in Oculopharyngeal Muscular Dystrophy (OPMD)
por: Harish, Pradeep, et al.
Publicado: (2023)

BB-301: a silence and replace AAV-based vector for the treatment of oculopharyngeal muscular dystrophy
por: Strings-Ufombah, Vanessa, et al.
Publicado: (2021)

P-7 Clinical and electrophysiological feature of 13 Italian patients with oculopharyngeal muscular dystrophy (OPMD)
por: Fiorillo, C., et al.
Publicado: (2011)

PABPN1 gene therapy for oculopharyngeal muscular dystrophy
por: Malerba, A., et al.
Publicado: (2017)

Correlation between PABPN1 genotype and disease severity in oculopharyngeal muscular dystrophy
por: Richard, Pascale, et al.
Publicado: (2017)

Nuclear entrapment and extracellular depletion of PCOLCE is associated with muscle degeneration in oculopharyngeal muscular dystrophy
por: Raz, Vered, et al.
Publicado: (2013)

Oculopharyngeal muscular dystrophy or oculopharyngeal distal myopathy: case report()
por: Maeda, Marilia Yuri, et al.
Publicado: (2015)

Recent Progress in Oculopharyngeal Muscular Dystrophy
por: Yamashita, Satoshi
Publicado: (2021)

A Japanese case of oculopharyngeal muscular dystrophy (OPMD) with PABPN1 c.35G > C; p.Gly12Ala point mutation
por: Nishii, Yo-suke, et al.
Publicado: (2021)

Mitochondrial Dysfunction Reveals the Role of mRNA Poly(A) Tail Regulation in Oculopharyngeal Muscular Dystrophy Pathogenesis
por: Chartier, Aymeric, et al.
Publicado: (2015)

Age-Associated Salivary MicroRNA Biomarkers for Oculopharyngeal Muscular Dystrophy
por: Raz, Vered, et al.
Publicado: (2020)

Activation of the ubiquitin-proteasome system contributes to oculopharyngeal muscular dystrophy through muscle atrophy
por: Ribot, Cécile, et al.
Publicado: (2022)

PABPN1 (GCN)11 as a Dominant Allele in Oculopharyngeal Muscular Dystrophy –Consequences in Clinical Diagnosis and Genetic Counselling
por: Richard, Pascale, et al.
Publicado: (2015)

Oculopharyngeal Muscular Dystrophy as a Paradigm for Muscle Aging
por: Raz, Yotam, et al.
Publicado: (2014)

Oculopharyngeal muscular dystrophy as a rare cause of dysphagia
por: Werling, Sarah, et al.
Publicado: (2015)

Behavioural Impairment and Frontotemporal Dementia in Oculopharyngeal Muscular Dystrophy
por: Tankink, Maurits, et al.
Publicado: (2022)

Assessment of PABPN1 nuclear inclusions on a large cohort of patients and in a human xenograft model of oculopharyngeal muscular dystrophy
por: Roth, Fanny, et al.
Publicado: (2022)

Dysphagia with fatal choking in oculopharyngeal muscular dystrophy: Case report
por: Chen, Andy Wei-Ge, et al.
Publicado: (2018)

Swallowing, Chewing and Speaking: Frequently Impaired in Oculopharyngeal Muscular Dystrophy
por: Kroon, Rosemarie H.M.J.M., et al.
Publicado: (2020)

Muscle ultrasound is a sensitive biomarker in oculopharyngeal muscular dystrophy
por: Kroon, Rosemarie H. M. J. M., et al.
Publicado: (2022)

The phenotypic and genotypic features of Chinese patients with oculopharyngeal muscular dystrophy
por: Lin, Feng, et al.
Publicado: (2023)

Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy
por: Zhou, Haiyan, et al.
Publicado: (2020)

Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy
por: Malerba, Alberto, et al.
Publicado: (2012)

RNA-Based Therapy Utilizing Oculopharyngeal Muscular Dystrophy Transcript Knockdown and Replacement
por: Abu-Baker, Aida, et al.
Publicado: (2019)

Oculopharyngeal muscular dystrophy misdiagnosed as myasthenia gravis: Case report and review of literature
por: Aryani, Omid, et al.
Publicado: (2017)

Systemic Antisense Therapeutics for Dystrophin and Myostatin Exon Splice Modulation Improve Muscle Pathology of Adult mdx Mice
por: Lu-Nguyen, Ngoc, et al.
Publicado: (2017)

Deregulation of the ubiquitin-proteasome system is the predominant molecular pathology in OPMD animal models and patients
por: Anvar, Seyed Yahya, et al.
Publicado: (2011)

Combined Therapies for Duchenne Muscular Dystrophy to Optimize Treatment Efficacy
por: Cordova, Gonzalo, et al.
Publicado: (2018)

Intranuclear inclusions in muscle biopsy can differentiate oculopharyngodistal myopathy and oculopharyngeal muscular dystrophy
por: Ogasawara, Masashi, et al.
Publicado: (2022)

Oculopharyngeal muscular dystrophy mutations link the RNA‐binding protein HNRNPQ to autophagosome biogenesis
por: Ishtayeh, Hasan, et al.
Publicado: (2023)

Choked: A Case Report of Oculopharyngeal Muscular Dystrophy Mimicking Hypothyroidism From the Philippines
por: Infante, Jerome M, et al.
Publicado: (2023)

Oculopharyngeal muscular dystrophy as a rare differential diagnosis for unexplained dysphagia: a case report
por: Bumm, Klaus, et al.
Publicado: (2009)

2396: Utility of the Modified Barium Swallow Impairment Profile as an outcome measure in oculopharyngeal muscular dystrophy
por: Youssof, Sarah, et al.
Publicado: (2018)

Longitudinal Assessment of Strength, Functional Capacity, Oropharyngeal Function, and Quality of Life in Oculopharyngeal Muscular Dystrophy
por: Kroon, Rosemarie H.M.J.M., et al.
Publicado: (2021)

Advances in gene therapy for muscular dystrophies
por: Abdul-Razak, Hayder, et al.
Publicado: (2016)

Over-expression of BCL2 rescues muscle weakness in a mouse model of oculopharyngeal muscular dystrophy
por: Davies, Janet E., et al.
Publicado: (2011)

Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy
por: Barbezier, Nicolas, et al.
Publicado: (2011)

Lithium chloride attenuates cell death in oculopharyngeal muscular dystrophy by perturbing Wnt/β-catenin pathway
por: Abu-Baker, A, et al.
Publicado: (2013)

An Antibody to Detect Alanine-Expanded PABPN1: A New Tool to Study Oculopharyngeal Muscular Dystrophy
por: Vest, Katherine E., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_782ve38em8jg2hu2npoieb8mrh